|
Status |
Public on Jul 09, 2019 |
Title |
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq) |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Three triple negative breast cancer cell lines (MDAMB231, SUM159, and HCC1806) were treated with small molecule inhibitors (JQ1, BET bromodomain inhibitor; GSK2801, BAZ2A/B bromodomain inhibitor) alone and in combination for 72 hours
|
|
|
Overall design |
12 experimental samples
|
|
|
Contributor(s) |
Johnson GL, Bevill SM |
Citation(s) |
31000582 |
|
Submission date |
Jul 10, 2018 |
Last update date |
Oct 08, 2019 |
Contact name |
Gary L Johnson |
E-mail(s) |
glj@med.unc.edu
|
Phone |
919-843-3107
|
Organization name |
UNC Chapel Hill SOM
|
Department |
Pharmacology
|
Lab |
Gary L. Johnson
|
Street address |
120 Mason Farm Road Genetic Medicine Building CB#7365
|
City |
Chapel Hill |
State/province |
North Carolina |
ZIP/Postal code |
27599 |
Country |
USA |
|
|
Platforms (1) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (12)
|
|
This SubSeries is part of SuperSeries: |
GSE116919 |
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination |
|
Relations |
BioProject |
PRJNA480603 |
SRA |
SRP153037 |